Ad5/F35-APE1 siRNA重组腺病毒联合光动力疗法对非小细胞肺癌治疗作用的实验研究
|
摘要
肺癌是人类最常见的恶性肿瘤之一,居恶性肿瘤死因的首位,其发病率及死亡率呈逐年上升的趋势。目前对肺癌的治疗方法有手术、放疗和化疗等,尽管这些治疗手段技术上均有了长足的进步,但是由于肺癌发生的分子机制及病理过程较为复杂,其5年生存率无明显提高,因此亟待探索新的肺癌治疗手段。光动力治疗(photodynamictherapy,PDT)是一种在有氧条件下,通过一定波长的激光激发靶细胞内光敏剂产生活性氧物质(reactive oxygen species,ROS)直接损伤肿瘤细胞、使微血管受损造成癌组织血流灌注减少的抗肿瘤新方法。但由于肿瘤细胞可能对其治疗过程中的氧化损伤及DNA损伤均具有一定的自身修复作用,影响了PDT对肿瘤的疗效。脱嘌呤/脱嘧啶核酸内切酶(apurinic apyrimidinic endonuclease,APE1)具有DNA损伤修复和氧化还原双功能,能通过调节生物体对氧化应激和缺氧的适应性,最大限度地减少细胞损伤。本研究以APE1为靶点,通过Ad5/F35-APE1 siRNA重组腺病毒,研究其体内对A549细胞感染效率和对APE1基因表达的“敲除”作用,及其体内及体外增强肺癌PDT敏感性的作用及机制。
研究目的
1.探讨APE1在非小细胞肺癌(non-small cell lung carcinomas,NSCLC)中的表达特点及其与患者预后的关系,为NSCLC以APE1靶点的基因治疗提供临床理论依据;
2.探讨以APE1为靶点的基因治疗联合PDT在肺癌治疗中的临床应用前景。
研究内容和方法
1.APE1在NSCLC组织中表达及其临床意义:采用免疫组化方法检测NSCLC组织APE1蛋白表达特点,分析APE1表达高低与预后的关系,为进一步以APE1为靶点的基因治疗提供临床病理基础。
2.Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞杀伤效应的实验研究:采用流式细胞术检测Ad5/F35-APE1 siRNA重组腺病毒对A549细胞感染效率;Westernblot检测其对A549细胞APE1基因的沉默作用;采用[γ-~(32)P]ATP标记寡核苷酸法检测Ad5/F35-APE1 siRNA重组腺病毒对A549细胞AP内切酶活性的抑制作用;通过MTT来检测PDT及Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞增殖抑制作用;流式细胞检测细胞凋亡;彗星实验检测DNA损伤;Western blot检测APE1蛋白及VEGF蛋白的表达。
3.Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞裸鼠移植瘤抑瘤作用的实验研究:建立肺腺癌A549细胞裸鼠移植瘤动物模型,观察Ad5/F35-APE1 siRNA重组腺病毒联合PDT对肺癌生长抑制的协同作用,TUNEL法检测肿瘤细胞细胞凋亡。
研究结果
1.APE1在NSCLC组织表达及其临床意义:正常肺组织及NSCLC组织均有APE1表达,但其表达的定位有所区别,正常肺组织以胞核表达为主,NSCLC组织以胞浆表达为主,两者之间差异性显著(P＜0.01);通过Kaplan-Meier生存分析提示:APE1高低表达组之间生存时间有显著性差异,APE1低表达组中位生存时间为35±5.196个月,APE1高表达组中位生存期为26±0.761个月。
2.Ad5/F35-APE1 siRNA重组腺病毒对A549细胞生物效应的实验研究:10 MOI的Ad5/F35-APE1 siRNA腺病毒对A549细胞的感染效率可达98%;Ad5/F35-APE1siRNA呈剂量依赖性地抑制A549细胞APE1蛋白表达,且能显著抑制A549细胞的AP内切酶活性。
3.Ad5/F35-APE1 siRNA重组腺病毒增强A549细胞PDT治疗敏感性及机制的实验研究:Ad5/F35-APE1 siRNA联合PDT能显著增强A549细胞的增殖抑制作用;Ad5/F35-APE1 siRNA增加PDT诱导的A549细胞凋亡;碱性彗星分析结果显示Ad5/F35-APE1 siRNA抑制PDT后A549癌细胞DNA修复能力;PDT可诱导A549细胞APE1及VEGF蛋白表达增强,但通过Ad5/F35-APE1 siRNA可抑制A549细胞PDT诱导的APE1及VEGF蛋白的表达。
4.Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞裸鼠移植瘤抑瘤作用的实验研究:体内实验结果显示Ad5/F35-APE1 siRNA+PDT组肿瘤生长较单纯PDT组明显被抑制,单纯Ad5/F35-APE1 siRNA组肿瘤抑制率为34.85%,单纯PDT组肿瘤抑制率为52.19%,Ad5/F35-APE1 siRNA+PDT组肿瘤抑制率为93.97%。TUNEL检测肿瘤细胞凋亡情况,显示Ad5/F35-APE1 siRNA+PDT组肿瘤细胞凋亡率为(24.68±2.47)%,显著高于Ad5/F35-APE1 siRNA感染组(6.24±1.32)%、单独PDT组(12.12±1.76)%以及对照组(3.37±1.28)%(p＜0.01)。
结论
1.APE1在NSCLC中有胞浆异位表达的倾向,且APE1表达的高低与肺癌的预后有关。
2.Ad5/F35-APE1 siRNA重组腺病毒容易感染肺腺癌A549细胞,且可特异性抑制A549细胞APE1蛋白表达,抑制A549细胞的AP内切酶活性。
3.Ad5/F35-APE1 siRNA重组腺病毒能显著增强A549细胞PDT敏感性,主要是通过两种机制实现的,一方面通过抑制A549细胞PDT后的DNA损伤修复能力;另一方面通过抑制A549细胞对PDT所致氧化损伤的修复能力。
4.PDT可诱导A549细胞APE1蛋白表达增强,但通过Ad5/F35-APE1 siRNA可抑制PDT诱导的APE1蛋白的表达。
5.Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞裸鼠移植瘤的抑瘤作用较单独PDT更为明显。
Lung cancer is one of the most common malignancies,and is the leading cause of cancer death world wide.Moreover,the incidence rate and mortality of lung cancer tend to increase.The 3 main types of treatment for lung cancer are surgery,radiation therapy and chemotherapy.Although there is a great progress in treatment of lung cancer,5-year survival rates have not significantly improved,owing to complicated molecular mechanism involved in the carcinogenesis and development of lung cancer.Therefore,it is urgent to explore new approach for treatment of lung cancer.Photodynamic therapy(PDT) involves the application of a photosensitizer activated by visible light to generate reactive oxygen species(ROS),which can result in anti-cancer effects through direct lethal direct lethal effects on tumor cells and vascular impairment which limit blood supply to tumor region. But DNA damage and oxidative damage self-repairing capability of tumor cells to PDT decrease sensitivity of tumor cells to PDT.The human apurinic/apyrimidinic endonuclease(APE1) play important role in DNA repair functions and response to oxidative stress and regulation of transcription factors.In this study,we investigated the effect of adenoviral vector Ad5/F35 carrying human APE1 siRNA on the sensitivity of PDT to human NSCLC in vivo and in vitro.
Objective
1.To research the expression of APE1 protein in NSCLC ceils,analyze the relationship between APE1 expression and prognosis of NSCLC patients,and determine that APE1 is an effective therapeutic target gene of NSCLC.
2.To investigate the perspective of clinical application of combined treatment of adenoviral vector Ad5/F35-mediated APE1 siRNA with photodynamic therapy for lung cancer.
Materials and Methods
1.The expression of APE1 protein in NSCLC cells and its significance.The expression of APE1 in NSCLC patients was detected by immunohistochemical staining.To demonstrate that APE1 is an effective therapeutic target gene of NSCLC,the relationship between expression of APE1 and prognosis of NSCLC patients was determined.
2.Efficacy of combination of Ad5/F35-APE1 siRNA with PDT therapy on A549 cells. The efficiency of infection of Ad5/F35-APE1 siRNA on A549 cells was assessed by flow cytometry and fluorescence.After transfection with Ad5/F35-APE1 siRNA,the protein levels of APE1 in A549 cells were evaluated by western blot The AP incision enzyme activity was evaluated by[γ-~(32)p]ATP-marked oligonucleotide assays.The effect of combination of PDT and Ad5/F35-APE1 siRNA transfection of A549 cell proliferation was assessed by MTT assay.DNA damage was investigated by comet analysis.The cell apoptosis was assessed by flow cytometry.The expression of APE1 and VEGF were detected by western blot
3.The models of naked mice bearing transplantation tumor were established.Then,the sizes of the tumors were measured and the relevant growth curves were created.Afterwards, cell apoptosis was assessed by TUNEL assay.
Results
1.APE1 was detected in both lung tissues and NSCLC.While in the lung tissue,it was mainly observed in nuclear,whereas in NSCLC tussues it was observed in plasma.As shown by Kaplan-Meier survival analysis,the survival time of APE1-high expression group (median survival time:35±5.196 months) was longer than that of APE1-low group(median survival time:.26±0.761 months).
2.The infection efficiency of 10 MOI Ad5/F35-APE1 siRNA on A549 cells is 98%. Ad5/F35-APE1 siRNA transfection may inhibit APE1 protein expression in a dose-dependent manner.In the meantime,AP incision enzyme activity can be significantly inhibited.
3.Application of PDT with Ad5/F35-APE1 siRNA transfection can significantly decrease the cell proliferation and increase the apoptosis rate of A549 cells.The results of comet assay showed that Ad5/F35-APE1 siRNA transfection can inhibit A549 cell DNA repairing ability after application of PDT.Ad5/F35-APE1 siRNA transfection can inhibit the increase in APE1 and VEGF protein induced by PDT.
4.The results of in vivo study showed that tumor control rate in Ad5/F35-APE1 siRNA+PDT mice(93.97%) was higher than that of Ad5/F35-APE1 siRNA mice(34.85%) or PDT mice(52.19%).The results of TUNEL assay showed that apoptosis rate of Ad5/F35-APE1 siRNA+PDT group(24.68±2.47%) was significantly higher than that of Ad5/F35-APE1 siRNA group(6.24±1.32%),PDT group(12.12±1.76%) or control group (3.37±1.28%).
Conclusion
1.Aberrant expression of APE1 in NSCLC may have a correlation with prognosis of lung cancer.APE1 seems to be a target for treating lung cancer,which may be of great clinical significance.
2.Ad5/F35-APE1 siRNA transfection can infect A549 cells easily,which might specifically knockdown their APE1 expression.Also,it can markedly weaken the activity of incision enzymes.
3.Ad5/F35-APE1 siRNA transfection significantly enhances sensitivity of A549 cells to PDT treatment,possibly through inhibition of DNA repairing capability after treatment with PDT,or via suppression of oxidation repairing of A549 cells in response to PDT.
4.PDT might upregulate the expression of APE1 in A549 cells.However, Ad5/F35-APE1 siRNA might reverse this elevation.
5.Combination of Ad5/F35-APE1 siRNA transfection with PDT can significantly inhibit the growth of transplantation tumors in naked mice.
研究目的
1.探讨APE1在非小细胞肺癌(non-small cell lung carcinomas,NSCLC)中的表达特点及其与患者预后的关系,为NSCLC以APE1靶点的基因治疗提供临床理论依据;
2.探讨以APE1为靶点的基因治疗联合PDT在肺癌治疗中的临床应用前景。
研究内容和方法
1.APE1在NSCLC组织中表达及其临床意义:采用免疫组化方法检测NSCLC组织APE1蛋白表达特点,分析APE1表达高低与预后的关系,为进一步以APE1为靶点的基因治疗提供临床病理基础。
2.Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞杀伤效应的实验研究:采用流式细胞术检测Ad5/F35-APE1 siRNA重组腺病毒对A549细胞感染效率;Westernblot检测其对A549细胞APE1基因的沉默作用;采用[γ-~(32)P]ATP标记寡核苷酸法检测Ad5/F35-APE1 siRNA重组腺病毒对A549细胞AP内切酶活性的抑制作用;通过MTT来检测PDT及Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞增殖抑制作用;流式细胞检测细胞凋亡;彗星实验检测DNA损伤;Western blot检测APE1蛋白及VEGF蛋白的表达。
3.Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞裸鼠移植瘤抑瘤作用的实验研究:建立肺腺癌A549细胞裸鼠移植瘤动物模型,观察Ad5/F35-APE1 siRNA重组腺病毒联合PDT对肺癌生长抑制的协同作用,TUNEL法检测肿瘤细胞细胞凋亡。
研究结果
1.APE1在NSCLC组织表达及其临床意义:正常肺组织及NSCLC组织均有APE1表达,但其表达的定位有所区别,正常肺组织以胞核表达为主,NSCLC组织以胞浆表达为主,两者之间差异性显著(P＜0.01);通过Kaplan-Meier生存分析提示:APE1高低表达组之间生存时间有显著性差异,APE1低表达组中位生存时间为35±5.196个月,APE1高表达组中位生存期为26±0.761个月。
2.Ad5/F35-APE1 siRNA重组腺病毒对A549细胞生物效应的实验研究:10 MOI的Ad5/F35-APE1 siRNA腺病毒对A549细胞的感染效率可达98%;Ad5/F35-APE1siRNA呈剂量依赖性地抑制A549细胞APE1蛋白表达,且能显著抑制A549细胞的AP内切酶活性。
3.Ad5/F35-APE1 siRNA重组腺病毒增强A549细胞PDT治疗敏感性及机制的实验研究:Ad5/F35-APE1 siRNA联合PDT能显著增强A549细胞的增殖抑制作用;Ad5/F35-APE1 siRNA增加PDT诱导的A549细胞凋亡;碱性彗星分析结果显示Ad5/F35-APE1 siRNA抑制PDT后A549癌细胞DNA修复能力;PDT可诱导A549细胞APE1及VEGF蛋白表达增强,但通过Ad5/F35-APE1 siRNA可抑制A549细胞PDT诱导的APE1及VEGF蛋白的表达。
4.Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞裸鼠移植瘤抑瘤作用的实验研究:体内实验结果显示Ad5/F35-APE1 siRNA+PDT组肿瘤生长较单纯PDT组明显被抑制,单纯Ad5/F35-APE1 siRNA组肿瘤抑制率为34.85%,单纯PDT组肿瘤抑制率为52.19%,Ad5/F35-APE1 siRNA+PDT组肿瘤抑制率为93.97%。TUNEL检测肿瘤细胞凋亡情况,显示Ad5/F35-APE1 siRNA+PDT组肿瘤细胞凋亡率为(24.68±2.47)%,显著高于Ad5/F35-APE1 siRNA感染组(6.24±1.32)%、单独PDT组(12.12±1.76)%以及对照组(3.37±1.28)%(p＜0.01)。
结论
1.APE1在NSCLC中有胞浆异位表达的倾向,且APE1表达的高低与肺癌的预后有关。
2.Ad5/F35-APE1 siRNA重组腺病毒容易感染肺腺癌A549细胞,且可特异性抑制A549细胞APE1蛋白表达,抑制A549细胞的AP内切酶活性。
3.Ad5/F35-APE1 siRNA重组腺病毒能显著增强A549细胞PDT敏感性,主要是通过两种机制实现的,一方面通过抑制A549细胞PDT后的DNA损伤修复能力;另一方面通过抑制A549细胞对PDT所致氧化损伤的修复能力。
4.PDT可诱导A549细胞APE1蛋白表达增强,但通过Ad5/F35-APE1 siRNA可抑制PDT诱导的APE1蛋白的表达。
5.Ad5/F35-APE1 siRNA重组腺病毒联合PDT对A549细胞裸鼠移植瘤的抑瘤作用较单独PDT更为明显。
Lung cancer is one of the most common malignancies,and is the leading cause of cancer death world wide.Moreover,the incidence rate and mortality of lung cancer tend to increase.The 3 main types of treatment for lung cancer are surgery,radiation therapy and chemotherapy.Although there is a great progress in treatment of lung cancer,5-year survival rates have not significantly improved,owing to complicated molecular mechanism involved in the carcinogenesis and development of lung cancer.Therefore,it is urgent to explore new approach for treatment of lung cancer.Photodynamic therapy(PDT) involves the application of a photosensitizer activated by visible light to generate reactive oxygen species(ROS),which can result in anti-cancer effects through direct lethal direct lethal effects on tumor cells and vascular impairment which limit blood supply to tumor region. But DNA damage and oxidative damage self-repairing capability of tumor cells to PDT decrease sensitivity of tumor cells to PDT.The human apurinic/apyrimidinic endonuclease(APE1) play important role in DNA repair functions and response to oxidative stress and regulation of transcription factors.In this study,we investigated the effect of adenoviral vector Ad5/F35 carrying human APE1 siRNA on the sensitivity of PDT to human NSCLC in vivo and in vitro.
Objective
1.To research the expression of APE1 protein in NSCLC ceils,analyze the relationship between APE1 expression and prognosis of NSCLC patients,and determine that APE1 is an effective therapeutic target gene of NSCLC.
2.To investigate the perspective of clinical application of combined treatment of adenoviral vector Ad5/F35-mediated APE1 siRNA with photodynamic therapy for lung cancer.
Materials and Methods
1.The expression of APE1 protein in NSCLC cells and its significance.The expression of APE1 in NSCLC patients was detected by immunohistochemical staining.To demonstrate that APE1 is an effective therapeutic target gene of NSCLC,the relationship between expression of APE1 and prognosis of NSCLC patients was determined.
2.Efficacy of combination of Ad5/F35-APE1 siRNA with PDT therapy on A549 cells. The efficiency of infection of Ad5/F35-APE1 siRNA on A549 cells was assessed by flow cytometry and fluorescence.After transfection with Ad5/F35-APE1 siRNA,the protein levels of APE1 in A549 cells were evaluated by western blot The AP incision enzyme activity was evaluated by[γ-~(32)p]ATP-marked oligonucleotide assays.The effect of combination of PDT and Ad5/F35-APE1 siRNA transfection of A549 cell proliferation was assessed by MTT assay.DNA damage was investigated by comet analysis.The cell apoptosis was assessed by flow cytometry.The expression of APE1 and VEGF were detected by western blot
3.The models of naked mice bearing transplantation tumor were established.Then,the sizes of the tumors were measured and the relevant growth curves were created.Afterwards, cell apoptosis was assessed by TUNEL assay.
Results
1.APE1 was detected in both lung tissues and NSCLC.While in the lung tissue,it was mainly observed in nuclear,whereas in NSCLC tussues it was observed in plasma.As shown by Kaplan-Meier survival analysis,the survival time of APE1-high expression group (median survival time:35±5.196 months) was longer than that of APE1-low group(median survival time:.26±0.761 months).
2.The infection efficiency of 10 MOI Ad5/F35-APE1 siRNA on A549 cells is 98%. Ad5/F35-APE1 siRNA transfection may inhibit APE1 protein expression in a dose-dependent manner.In the meantime,AP incision enzyme activity can be significantly inhibited.
3.Application of PDT with Ad5/F35-APE1 siRNA transfection can significantly decrease the cell proliferation and increase the apoptosis rate of A549 cells.The results of comet assay showed that Ad5/F35-APE1 siRNA transfection can inhibit A549 cell DNA repairing ability after application of PDT.Ad5/F35-APE1 siRNA transfection can inhibit the increase in APE1 and VEGF protein induced by PDT.
4.The results of in vivo study showed that tumor control rate in Ad5/F35-APE1 siRNA+PDT mice(93.97%) was higher than that of Ad5/F35-APE1 siRNA mice(34.85%) or PDT mice(52.19%).The results of TUNEL assay showed that apoptosis rate of Ad5/F35-APE1 siRNA+PDT group(24.68±2.47%) was significantly higher than that of Ad5/F35-APE1 siRNA group(6.24±1.32%),PDT group(12.12±1.76%) or control group (3.37±1.28%).
Conclusion
1.Aberrant expression of APE1 in NSCLC may have a correlation with prognosis of lung cancer.APE1 seems to be a target for treating lung cancer,which may be of great clinical significance.
2.Ad5/F35-APE1 siRNA transfection can infect A549 cells easily,which might specifically knockdown their APE1 expression.Also,it can markedly weaken the activity of incision enzymes.
3.Ad5/F35-APE1 siRNA transfection significantly enhances sensitivity of A549 cells to PDT treatment,possibly through inhibition of DNA repairing capability after treatment with PDT,or via suppression of oxidation repairing of A549 cells in response to PDT.
4.PDT might upregulate the expression of APE1 in A549 cells.However, Ad5/F35-APE1 siRNA might reverse this elevation.
5.Combination of Ad5/F35-APE1 siRNA transfection with PDT can significantly inhibit the growth of transplantation tumors in naked mice.
引文
1.Jemal A,Clegg LX,Ward E,et al..Annual report to the nation on the status of cancer,1975-2001,with a special feature regarding survival.Cancer.2004;101:3-27
2.杨玲,李连弟,陈育德,等.中国肺癌死亡趋势分析及发病、死亡的估计与预测(J).中国肺癌杂志,2005,8(4):274.
3.许德余.肿瘤光动力疗法[M].北京:中国医药科技出版社,1996:88-95.
4.Evans AR,Limp-Foster M,Kelley MR.Going APE over ref-1.Mutat Res 2000;461:83-108
5.Shen JC,Loeb LA.Mutations in the alpha8 loop of human APE1 alter binding and cleavage of DNA containing an abasic site.J Biol Chem,2003,278(47):46994-47001.
6.Wong D,DeMott MS,Demple B.Modulation of the 3′→5′exonuclease activity of human apurinic endonuclease(Ape1) by its 5′-incised Abasic DNA product.J Biol Chem,2003,278(38):36242-36249.
7.Bennett RA,Wilson DM,Wong D,et al.Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway.Proc Natl Acad Sci USA,1997,94(14):7166-7169.
8.Marsin S,Vidal AE,Sossou M,et al.Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1.J Biol Chem,2003,278(45):44068-44074.
9.Tell G,Pines A,Paron I,et al.Redox effector factor-1 regulates the activity of thyroid transcription factor 1 by controlling the redox state of the N transcriptional activation domain.J Biol Chem,2002,277(17):14564-14574.
10.Borkhardt,A.Blocking oncogenes in malignant cells by RNA interference:new hope for a highly,specific cancer treatment.Cancer Cells,2002;2:167-168.
11.Volpers C,Kochanek S.Adenoviral vectors for gene transfer and therapy.J Gene Med,2004,Suppl 1:S164-71.
12.储大同.肺癌.北京:北京大学医学出版社.2007:7-14.
13.Angkeow P,Deshpande SS,Qi B et al.Redox factor-1:an extra-nuclear role in the regulation of endothelial oxidative stress and apoptosis.Cell Death Differ,2002,9(7):717-725
14.Hall JL,Wang X,Van Adamson et al.Overexpression of Ref-1 inhibits hypoxia and tumor necrosis factor-induced endothelial cell apoptosis through nuclear factor-kappab-independent and -dependent pathways.Circ Res,2001,88(12):1247-1253
15.Bennett RA,Wilson DM 3rd,Wong D,et al.Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway.Proc Natl Acad Sci USA,1997,94(14):7166-7169.
16.Fry WA,Phillips J,Menck H.Ten-year survey of lung cancer treatment and survival in hospitals in the United States:a national cancer data base report[J].Cancer,1999,86(9):1867-1876.
17.Friedberg EC.DNA damage and repair.Nature,2003,421(6921):436-440.
18.Ishikawa T,Samuel S.Zhang M.et al..DNA repair and cancer:Lessons from mutant mouse models.Cancer Sci 2004;95:112-117.
19.Bruner SD,Noman DP,Verdine CL et al.Structural basis for recognition and repair of the endogenous mutagen 8-oxogua in DNA.Nature,2000,403(6772):859
20.Wood RD,Mitchell M,Sgouros J et al.Human DNA repair genes.Science,2001,291(5507):1284
21.Evans AR,Limp-Foster M,Kelley MR.Going APE over ref-1.Mutat Res 2000;461:83-108
22.吕晓华,王瑞淑.Ref-1:一种调节细胞氧化还原状态的多功能蛋白质.国外医学分子生物学分册 2001;23(3):65-9
23.Puglisi F,Barbone F,Tell G et al.Prognostic role of Ape/Ref-1 subcellar expression in stage Ⅰ-Ⅲ breast carcinomas.Oncol Rep,2002,9(1):11-17
24.Moore DH,Michael H,Tritt R et al.Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers.Clin Cancer Res,2000,6(2):602-609
25.Kelley MR,Cheng L,Foster R et al.Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer.Clin Cancer Res,2001,7(4):824-830.
26.Kakolyris S,Kaklamanis L,Giatromanolaki A,et al.Expression and subcellular locaLization of human AP endonuclease 1(HAP1/Ref-1) protein:a basis for its role in human disease[J].Histopathology,1998,33(6):561-569.
27. TELL G, DAMANTE G,1 CALDWELL D, et al. The Intracellular Localization of APE1/Ref-1:More than a Passive Phenomenon? Antioxid. Redox Signal. 7, 2005(3,4):367 - 384.
28. Herring CJ, West CM, Wilks DP, et al. Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivityof cervical cancers. Br J Cancer. 1998, 78(9): 1128-1133
29. Puglisi F, Aprile G, Minisini AM, et al. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. Anticancer Res 2001;21(6A):4041-9.
30. Kakolyris S, Giatromanolaki A, KoukourakisM, et al. Nuclear location of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early Operable non-small cell lung cancer (NSCLC) [J]. J Pathol, 1999, 189(3): 351-357.
31．仲召阳,王东,李增鹏,等。骨肉瘤中APE1的表达及其与血管生成的关系[J]。 第三军医大学学报,2005,27(10)：1045-1048．
32. Killilea DW, Hester R, Balczon R, et al. Free radical production in hypoxic pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2000, 279(2): L408-412.
33. Grishko V, Solomon M, Breit JF, et al. Hypoxia promotes oxidative base modifications in the pulmonary artery endothelial cell VEGF gene. FASEB J, 2001, 15(7): 1267-1269.
34. Ziel KA, Campbell CC, Wilson GL, et al. Ref-1/Ape is critical for formation of the hypoxia-inducible transcriptional complex on the hypoxic response element of the rat pulmonary artery endothelial cell VEGF gene. FASEB J, 2004, 18(9): 986-998.
35. Hall JL ,Wang X, Van Adamson V, et al. Overexpression of Ref-1 inhibits Hypoxia and tumor necrosis factor-induced endothelial cell apoptosis Through nuclear factor-kappab-independent and-dependent pathways[J]. CircRes, 2001, 88(12): 1247-1253.
36. Thomas J. Dougherty, Charles J. Gomer, Barbara W. Henderson, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905
37. Zhu TC, Hahn SM, Kapatkin AS, et al. In vivo optical properties of normal canine prostate at 732nm using motexafin lutetium-mediated photodynamic therapy[J]. Photochem Photobiol, 2000,77(1): 81-8.
38. Akita Y, Kozaki K, Nakagawa A, et al. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity [J]. Br J Dermatol, 2004,151(2): 472-80.
39. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther, 2004, 3(6): 679-686.
40. Fung H, Demple B. A vital role for Apel/Refl protein in repairing spontaneous DNA damage in human cells, Mol Cell, 2005, 17(3):463-470.
41. Raffoul JJ, Banerjee S , Gupta VS, et al. Down-regulation of Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Expression by Soy Isoflavones Enhances Prostate Cancer Radiotherapy In vitro and In vivo. [J]Cancer Res 2007;67(5):2141 - 9.
42. Nguyen T, Menocal EM, Harborth J, Fruehauf JH, et al. RNAi therapeutics: An update on delivery.. Curr Opin Mol Ther. 2008 10(2): 158-167.
43. Paddison PJ ,Caudy AA ,Hannon GJ . Stable suppression of gene expression by RNAi in mammalian cells (J) . Proc Natl Acad Sci USA ,2002 ,99 (3): 1443.
44. Brummelkamp TR ,Bernards R ,Agami RA. System for stable expression of short interfering RNAs in mammalian cells (J ) . Science ,2002 ,296 (5567) :550.
45. Paul CP , Good PD ,Winer I ,et al . Effective expression of small interfering RNA in human cells (J ) . Nature Biotechnology ,2002 ,20 (5):505.
46. Shuey D , McCallus DE , Giordano T. RNAi : gene silencing in the rapeutici intervention (J) . Drug Discov Day , 2002 , 7 ( 20): 1040.
47. Fan Z, Beresford PJ, Zhang D, et al. Cleaving the oxidative repair protein Apel enhances cell death mediated by granzyme A. Nat Immunol, 2003, 4(2): 145-153.
48. Renee Ho, Lyudmila I. Rachek, Yi Xu, et al. Yeast apurinic/apyrimidinic endonuclease Apnl protects mammalian neuronal cell line from oxidative stress. J. Neurochem. 2007, 7( 10): 1459-1471.
49. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res, 2006, 4(3): 218-227.
50. Weber W, Fussenegger M. Pharmacologic transgene control systems for gene therapy [J] . J Gene Med , 2006 , 8(5) :533-534.
51. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther, 2005, 16(9): 1016-1027.
52. .Buchschacher GL . Introduction to retroviruses and retroviral vectors [J ] . Somat Cell Mol Genet, 2001 ,26(1): 1211.
53. J ames B , Wechuck , Ozuer A , et al . Effect of temperature ,medium composition , and cell passage on production of herpesbased viral vectors [J ] . Biotech and Bioengin,2002,79(1):112-119.
54. Mona ha n PE , Samulski RJ . Adeno-associated virus vectors for gene therapy:more pros than cons [J ] . Mol Med Today , 2000 ,6 (2) :433-440.
55. Roth JA , Cristiano RJ. Gene therapy for cancer: what have we done and where are we going [J] . J Natl Ca ncer Inst, 1997 , 89(1) :21-39.
56. Gomez-Navarro J , Curiel DT , Douglas JT. Gene therapy for cancer [J] . Eur J Cancer , 1999 , 35 (3) :867-885.
57. Hit t MM , Gauldie J . Gene vectors for cytokine expression in vivo [J ] . Cur r Pharm Des , 2000 , 6 (3) :613-632.
58. Mountain A. Gene therapy : the f irst decade [ J ] . Trends Biotechnol , 2000 , 18 (1):119-128.
59. George JA. Gene therapy progress and prospects: adenoviral vectors [J ] . Gene Ther, 2003, 10(6) :1135-1141.
60. Romano G , Michell P , Pacilio C , et al . Latest developments in gene transfer technology : achievements , perspectives , and controversies over therapeutic applications [ J ] . Stem Cells , 2000 ,18(1): 19-39.
61. .Nishikawa M , Huang L . Non viral vectors in the new millennium:delivery barriers in gene transfer [J ] . Hum Gene Ther, 2001 ,12(4):861-870.
62. Thomas A , Ratko T , Joseph P , et al . Clinical Gene Therapy for Nonmalignant Disease [J ] . The American J of Med , 2003 ,115 (3) :560-569.
63. Kminiski JM , Huber MR , Summers JB , et al . Design of anonviral vector for site-selective , efficient integration into the human genome [J ] . FASEB J , 2002 ,16 (10): 1242-1247.
64. Emery DW , Yannaki E , Tubb J , et al . A chromatin insulator protects retrovirus vectors from chromosomal position effects[J ] . Proc Natl Acad Sci USA , 2000 , 97 (10):9150-9155.
65. Wu N , Watkins SC , Schaffer PA , et al . Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate early genes encoding ICP4、 ICP27 and ICP22 [J ] . J Virol, 1996 , 70 (6) :6358-6369.
66. .Marconi P , Krisky D , Oligino T , et al . Replication-defective herpes simplex virus vectors for gene transfer in vivo [J] . ProcNatl Acad Sci USA , 1996 , 93:11319-11320.
67. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE , et al . Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
68. Duxbury MS,Matros E,Ito H,et al.Systemic siRNAmediatedgene silencing:a new approach to targetedtherapy of cancer[J].Ann Surg,2004,240(4):667.
69. .Reuven Agami. RNAi and related mechanisms and their potential use for therapy. Current Opinion in Chemical Biology, 2002, 6: 829-834.
70. .Harbort h J , Elbashir S M , Bechert K, et al . Identification of essential genes in cultured mallian cells using small interfering RNAs. J Cell Sci ,2001 , 114(24):4557-4565.
71. Gonzalez-Santos ,Juana M , Cao H , et al . A complementation method for functional analysis of mammalian genes. NucleicAcids Res ,2005 ,33 (10): 94.
72. .Brummelkamp TR, Bernards R, Agami R.A system for stable expression of short interfering RNAs in mammalian cells. Science, 2002, 296(5567): 550-553.
73. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol, 2006, 133(1): 9-29.
74. Majhen D, Ambriovic-Ristov A. Adenoviral vectors-How to use them in cancer gene therapy? Virus Res, 2006,119(2): 121-133.
75. .Relph KL, Harrington KJ, Pandha H. Adenoviral strategies for the gene therapy of cancer. Semin Oncol, 2005, 32(6): 573-582.
76. Lee YJ, Imsumran A, Park MY, et al. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway. Lung Cancer, 2007, 55(3): 279-286.
77. Lin L, Chen L, Wang H, et al. Adenovirus-mediated transfer of siRNA against Runx2/Cbfa1 inhibits the formation of heterotopic ossification in animal model. Biochem Biophys Res Commun, 2006, 349(2): 564-572.
78. Koizumi N, Mizuguchi H, Hosono T, et al. Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. Biochim Biophys Acta, 2001, 1568(1): 13-20.
79. Li Y, Pong RC, Bergelson JM, et al.. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res, 1999, 59(2): 325-330.
80. Miller CR , Buchsbaum DJ , Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res, 998, 58(24): 5738-5748.
81. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, et al. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol, 2000, 74(6): 2567-2583.
82. Nilsson M , Ljungberg J , Richter J, et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med, 2004, 6(6): 631-641.
83. Havenga MJ, Lemckert AA, Ophorst OJ, et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol, 2002, 76(9): 4612-4620.
84. McCaughan J S J r. Photodynamic therapy : a review. Drug Aging ,1999 ,15 (1) '. 49-68.
85．孟斌,温博贵,李冠武,等．肿瘤光动力疗法诱导细胞凋亡机制研究进展[J]．生理科学进展,2002,33(3)：269—272．
86. FingarVH, Kik PK, Haydon PS, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD)[ J ]. Br-J-Cancer, 1999, APR: 79 (11): 1702.
87. Agarwal ML , Clay ME , Harvey EJ , et al.Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res, 1991 , 51 ( 21 ) : 5993-5996.
88.Krammer B.Vascular effects of photodynamic therapy.Anticancer Res,2001,21(6B):4271-4277.
89.Gollnick SO,Vaughan L,Henderson BW.Generation of effective antitumor vaccines using photodynamic therapy.Cancer Res,2002,62(6):160421608.
90.Korbelik M,Sun J,Posakony JJ.Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors.Photochem Photobiol,2001,73(4):403-409.
91.Chiu SM,Oleinick NL.Dissociation of mitochondrial depolarization from cytochrome crelease during apoptosis induced by photodynamic therapy.Br J Cancer,2001,84(8):1099-1106.
92..Kim HR,Luo Y,Li G,et al.Enhanced apoptotic response to photodynamic therapy after bcl22 transfection.Cancer Res,1999,59(14):3429-3432.
93.赵玉沛,杨波,张太平,等.血卟啉衍生物光动力作用杀伤人胰腺癌细胞的实验研究[J].中华外科杂志,2000,38(3):204-207。
94.Olive PL.DNA damage and repair in individual cells:applications of the comet assay in radiobiology.Int J Radiat Biol,1999,75(4):395-405.
95.Wang HW,Putt ME,Emanuele M J,et al.Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome[J].Cancer Res,2004,64(20):7553-61.
96.Masumoto K,Yamada I,Tanaka H,et al.Tissue distribution of a new photosensitizer ATX-S 10Na(Ⅱ) and effect of a diode laser(670nm) in photodynamic therapy[J].Lasers Med Sci,2003,18(3):134-8.
97.Ahmad N,Mukhtar H.Mechanism of photodynamic therapy-induced cell death[J].Methods Enzymol,2000,319:342-58.
98.Dolmans DE,Fukumura D,Jain RK.Photodynamic therapy for cancer.Nat Rev Cancer 2003;3:380-7.
99.Brown SB,Brown EA,Walker I.Photodynamic Therapy(PDT) for Malignant and Pre-malignant Indications.Lancet Oncol.2004 Aug;5(8):497-508
100.Lai J,Tao Z,Xiao J,et al.Effect of photodynamic therapy(PDT) on the expression of proapoptotic protein Bak in nasopharyngealcarcinoma(NPC).Lasers Surg Med,2001,29(1):27-32.
101.Uehara M , Inokuchi T , Sano K, et al. Expression of vascular endothelial growth factor in mouse tumours subjected to photodynamic therapy. Eur J Cancer ,2001 ,37 (16) : 2111-2115.
102.Korbelik M , Sun J , Posakony JJ . Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem Photobiol ,2001 ,73 (4) : 403-409.
103.Orenstein A ,Kostenich G ,Roitman L ,et al. A comparative study of tissue distribution and photodynamic therapy selectivity of chlorine- e6 ,Photofrin II and ALA2induced protoporp hyrin Kinacolon carcinoma model (J ) .Br J Cancer ,1996 ,73 (8) :937.
104.Wyld L, Reed MW, Brown NJ. Differential cell death reponse to photodynamic therapy is dependent on dose and cell type[J]. Br J Cancer, 2001, 84(10): 1384-1386.
105.Xue L Y, He J , Oleinick NL. Rapid tyrosine phosphorylation of HS1 in the response of mouse lymphoma L5178Y2R cells to photodynamic treatment sensitized by the phthalocyanine Pc 4. Photochem Photobiol, 1997 , 66(1) :105-113.
106.Ruck A, Heckelsmiller K, Kaufmann R, et al. Light-induced apoptosis involves a defined sequence of cytoplasmic and nuclear calcium release in lPcS4-photosensitized rat bladder RR 1022 epithelial cells[J]. Photochem Photobiol, 2000, 72(2):210-216.
107.Silva JC, Lacava ZG, Kuckelhaus S, et al. Evaluation of the use of low level laser and photosensitizer drugs in healing[J]. Lasers Surg Med, 2004, 34(5):451-457.
108.Uzdensky A, Juzeniene A, Ma LW, et al. Photodynamic inhibition of enzymatic detachment of human cancer cells from a substratum. [J]. Biochim Biophys Acta 2004 Jan; 1670(1): 1-11.
109.Walker LJ, Craig RB, Harris AL, et al. A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res, 1994, 22(23):4884-4889.
110.Ono Y, Furuta T, Ohmoto T, et al. Stable expression in rat glioma cells of sense andantisense nucleic acids to a human multifunctional DNA repair enzyme APEX nuclease. Mutat Res, 1994, 315(1):55-63.
111.McNeill DR, Wilson DM 3rd. A dominant-negative form of the major human abasicendonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res, 2007, 5(1):61-70.
112..Yang ZZ,Chen XH,Wang D.Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector.Clin Lymphoma Myeloma.2007,7(4):296-304.
113.孙敬方.动物实验方法学[M].北京:人民卫生出版社,2001:391-396.
114.Rygaard J,Povlsen CO.Heterotransplantation of a human malignant tumor to 'nude'mice[J].Acta Path Microbiol Scand,1969;77:758-760.
115.田庆锷,李玛琳.人肿瘤细胞悬液裸鼠皮下接种及影响移植成功的因素[J].实验动物科学与管理,2004;21:47-48.
116.An Z,Wang X,Kubota T,et al.A clinical nude mouse metastatic model for highly malignant human pancreatic cancer[J].Anticancer Res,1996,16(2):627-631.
117.Shoji T,Konno H,Sakaguchi T,et al.Orthotopic implantation of a colon cancer xenograf t induces high expression of cyclooxygenase-2[J].Cancer Lett,2003,195(2):235-241
118.Tanaka E,Yamashita J,Hayashi N.A pulmonary metastatic model of human non-small cell lung carcinoma cells that produce a neut rophil elastase21ike molecule in severe combined immunodeficiency mice[J].Chest,2003,123(4):1248-1253.
119..王允,周清华,覃扬,等.外源性FHIT基因表达对肺腺癌细胞株A549恶性表型的逆转作用[J].中华医学遗传学杂志,2002,19(3):225-229.
120..Enebrecht BW,Menon C,Kachur AV,et al.Photofrin2mediated photodynamic therapy induces vascular occlusion and apoptosis in a humansarcoma xenograft model.Cancer Res,1999,59:4334-4342.
121.Fingar VH,Wieman TJ,Doak KW.Role of thromboxane andprostacyclin release on photodynamic therapy2induced tumor destruction.Cancer Res,1990,50:2599-2603.
122.Uehara M,Inokuchi T,Sano K,et al.Expression of vascular endothelial growth factor in mouse tumours subjected to photodynamic therapy.Eur J Cancer,2001,37(16)2111-2115.
123.Renno RZ,Delori FC,Holzer RA,et al.Photodynamic therapy using Lu-Tex inducesapoptosis in vitro,and its effect is potentiated by angiostatin in retinal capillary endothelial cells.Invest Ophthalmol Vis Sci,2000,41(12):3963-3971.
1.McCaughan J S J r.Photodynamic therapy:a review.Drug Aging,1999,15(1)49-68.
2.Lipson RL,Baldes EJ,Olaen AM.The useof derivative of hematoporphyrin in tumor detection.J Natl Cancer Inst,1961,26(1):1-8.
3.Hayata Y,Kato H,Konaka C,et al.Fiberoptic bronchoscopic laser photoradiation for tumor localization in lung cancer.Chest,1982,82(1):10-14.
4..Dolmans D,Fukumura D,Jain R.Photodynamic therapy for cancer[J].Nat Revancer,2003,3(5):380-387.
5.Bonnett R.Photosensitizers of porp hyrin and p ht halocyanine series for photodynamic t herapy[J].Chem Soc Rev,1995,24:19.
6.Kennedy J C.ALA2PDT An Overview[J].Photochemist ry and Photobiology.(Supply),1993,57:765.
7.Kawamoto C.Proceedings of the 1st International Conference on the Clinical Applications of Photosensitization for Diagnosis and Treatment[J].Tokyo,Japan,1986:130.
8.Scott LJ,Goa KL.Verteporfin.Drugs Aging,2000,16(2):139-146.
9..陈五高.激光治癌[M].武汉:华中师范大学出版社,1993:202.
10.Moghissi K,Dixon K.Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer? Eur Respir J,2003,22(3):535-541.
11.凌一鸣.脉冲激光和连续激光作光动力学治疗作用机制差异的探讨.中国激光医学杂志,1994,3(3):178.
12.Patelli M,Lazzari Agli L,Poletti V,et al.Photodynamic laser therapy for the treatment of early2stage bronchogenic carcinoma.Monaldi Arch Chest Dis,1999,54(4):315-318.
13.Huang Z,Chen Q,Shakil A,et al.Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy.Photochem Photobiol.2003Nov;78(5):496-502.
14.Chen Q,Huang Z,Chen H,et al.Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol. 2002 Aug;76(2):197-203
15.Matzi V, Maier A, Sankin O, et al., Photodynamic therapy enhanced by hyperbaric oxygenation in palliation of malignant pleural mesothelioma: clinical experience. Photodiag Photodyn Therapy 2004; 1:57-64
16. Huang Z, Chen Q, Chen H, ,et al., Effects of Pd-bacteriopheophorbide (TOOKAD)-Mediated Photodynamic Therapy on Canine Prostate Pretreated with Ionizing Radiation . Radiat Res. 2004 June; 161(6): 723-731.
17. Uzdensky A ,J uzeniene A ,Ma L ,et al. Photodynamic inhibition of enzymatic detachment of human cancer cells from a substratum[J] . Biochim Biophyscta ,2004 ,1670(1): 1-11.
18. Agarwal ML , Clay ME , Harvey EJ , et al.Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res , 1991 , 51 (21 ) : 5993-5996.
19. Lai J , Tao Z , Xiao J , et al. Effect of photodynamic therapy ( PDT) on the expression of proapoptotic protein Bak in nasopharyngeal carcinoma (NPC) . Lasers Surg Med ,2001 ,29(1) :27-32.
20. Chiu SM , Oleinick NL. Dissociation of mitochondrial depolarization from cytochrome crelease during apoptosis induced by photodynamic therapy. Br J Cancer , 2001 , 84 (8) : 1099-1106.
21. Almeida RD, Manadas BJ, Carvalho AP, et al. Intracellular signaling mechanisms in photodynamic therapy [ J ]. Biochim Biophys Acta, 2004, 1704:59-86
22. Piette J, Volanti C, Vantieghem A,et al. Cell death and growth arrest in response to photosensitizers[ J].Biochem Pharmacol,2003,66:1651-1659.
23. Whitacre CM,Satoh TH,Xue L,et al.Photodynamic therapy of human breast cancer xenografts lacking caspase3[J].Cancer Lett,2002,179:43-49.
24. He J,Agarwal ML,Larkin HE,et al.The induction of partial resistance . Photochem Photobiol, 1996,64:845-852.
25. Zhou ZH, Yang HG, Zhang ZY, et al.. Role of calcium in phototoxicity of 2-butylamino-2-demethoxy-hypocrellin A to human gastric cancer MGC-803. Biochim BiophysActa 2003; 1593: 191-200
26. DING X, XU Q, LIU F, et al. Hematoporphyrin monomethyl ether photodynamic damage on HeLa cells by means of reactive oxygen species production and cytosolic free calcium concentration elevation Cancer Letter, 2004,216(1):43-54
27. Du, H Y et al. Photoactivation of hypericin down-regulates glutathione S-transferase activity in nasopharyngeal cancer cells Cancer Lett, 2004,207:175-81
28. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what,where,why,and how[J].Photochem Photobiol Sci,2002, 1:1-21.
29. Henderson B , Fingar V. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model [J] .Photochem Photobiol , 1989 , 49 ( 3 ): 299-304.
30. Kobayashi W,Liu Q ,Matsumiya T ,et al.Photodynamic therapy upregulates expression of Mac - 1 and generation of leukotriene B ( 4 ) by human polymorphonuclear leukocytes [ J ] . Oral Oncol, 2004 ,40 (5) .506-510.
31.Krammer B. Vascular effects of photodynamic therapy. Anticancer Res , 2001 , 21 (6B) :4271-4277.
32. Dolmans DE , Kadambi A , Hill J S , et al.Vascular accumulation of a novel photosensitizer , MV6401 , causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res, 2002 , 62 ( 7 ) :2151-2156.
33. Henderson BW, Sitnik2Busch TM , Vaug-han LA. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent .Photochem Photobiol ,1999 ,70 (1) : 64-71.
34. Uehara M , Inokuchi T , Sano K, et al. Expression of vascular endothelial growth factorin mouse tumours subjected to photodynamictherapy. Eur J Cancer ,2001 ,37 (16) : 2111-2115.
35. Renno RZ , Delori FC , Holzer RA , et al.Photodynamic therapy using Lu2Tex induces apoptosis in vitro , and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci ,2000 ,41 (12) : 3963-3971.
36. Ichikawa K, Takeuchi Y, Yonezawa S , et al. Antiangiogenic photodynamic therapy( PDT ) using Visudyne causes effective suppression of tumor growth [ J ] . Cancer Lett ,2004 ,205 (1):39-48
37. Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamictherapy. Cancer Res 1996;56:5647-52.
38. Cecic I, Korbelik M, et al. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumours. Cancer Lett 2002; 183: 43-51.
39. Gollnick SO , Vaughan L , Henderson BW.Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res : 2002 ,62 (6) : 1604-1608.
40. Gollnick SO, Owczarczak B, Maier P. Preclinical Reports Photodynamic therapy and anti-tumor immunity [ J ] . Lasers in Surgery and Medicine,2006, 38( 5): 509 - 515
41. Korbelik M , Sun J , Posakony JJ . Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem Photobiol ,2001 ,73 (4) : 403-409.
42. Dougherty TJ , Gomer CJ , Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst, 1998 ,90(12) : 889-905.
43. Dougherty TJ . An update on p hotodynamic t herapy applications (J) J Clin Laser Med Sury,2002,20(1):3.
44. Edell ES , Cortese DA. Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection. Chest , 1992 , 102 (5) : 1319-1322.
45. Furuse K, Fukuoka M , Kato H , et al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early2stage lung cancer. The Japan LungCancer Photodynamic Therapy Study Group.J Clin Oncol ,1993 ,11 (10) : 1852-1857.
46. Kato H. Photodynamic therapy for lung cancer-a review of 19 years' experience. J Photochem Photobiol B ,1998 ,42 (2) : 96-99.
47. Dougherty TJ , Gomer CJ , Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst, 1998 ,90(12) :889-905.
48.Moghissi K,Dixon K,Hudson E,et al.Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd-YAG laser and photodynamic therapy.Thorax,1997,52(3):281-283.
49.Moghissi K,Dixon K,Stringer M,et al.The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer:experience of 100 cases.Eur J Cardiothorac Surg,1999,15(1):126.
50.Overholt BE Panjehpour M,Haydek JM.Photodynamic therapy for Barrett's esophagus:follow-up in 100 patients.Gastrointest Endosc,1999,49:123-226
51.Savarf JF,Grosjean P,Monnier P,et al.Photodynamic therapy of early squamous cell carcinomas of the esophagus:a review of 31 cases.Endoscopy,1998,30(3):258-263
52.张南征,朱云,潘武等.光动力疗法治疗食管贲门癌110例分析.徐州医学院学报,2001,21(4):291-294.
53.林文杰,陈俊辉,王少彬等.Photofrin光动力治疗食管癌近期疗效观察.医药产业资讯,2005,2(11):15-17
54.沙卫红,李瑜元,聂玉强等.光动力疗法与支架防止术治疗进展期食管癌比较.中华消化内镜杂志,2006,23(1):27
55.Ana P.Castano,PawelMrozMichael R.Hamblin,Photodynamic therapy and anti-tumour immunity.Nature Rev,2006,7(6):535
56.Sun,S.C.&Xiao,G.Deregulation of NF-κB and its up stream kinases in cancer.CancerMetastasis Rev,2003,22:405
57.Korbelik,M.& Sun,J.Cancer treatment by photodynamic therapy combined with adop tive immunotherapy using genetically altered natural killer cell line.Int.J.Cancer 2001,93-96.
58.Holyoke ED.New surgical approaches to pancreatic cancer.Cancer,1981,47(6):1719-1723.
59.Bown SG,Rogowska AZ,Whitelaw DE,et al.Photodynamic therapy for cancer of the pancreas.Gut,2002,50(4):549-557.
60.Laftavi MR,Lens P,Margonari J,et al.Photodynamic therapy can selectively eradicate pancreas exocrine secretion.Transplant Proc,1998,30(2):596-598.
61.Rahbar M,Lenz P,Margonari J,et al.Destruction of rat exocrine pancreatic tissue by photodynamic therapy. Transplant Proc , 1997 ,29 (7): 2904-22907.
62. Nakamura H, yanai H, Nishikawa J, et al. Experience with photodynamic therapy (endoscop ic laser therapy) for the treatment of early gastric cancer. Hepatogastroenterology, 2001, 48: 1599-1603.
63. Haramura T, Fukui H, Ishii Y, et al. Shape memory alloy loop snare for endoscop ic photodynamic therapy of early gastric cancer. Endoscopy, 2000, 32 (8): 69.
64. Yanai H, Kuroiwa Y, Shimizu N, et al. The pilot experience of immunotherapycombined photodynamic therapy for advanced gastric cancer in elderly patients. Int J Gastrointest Cancer, 2002, 32 (223): 139-142.
65. Karanow SI. Long term results after photodynamic therapy (PDT) of T1N0M0 gastrointestinal ( GI) tumors. Hepatogastroenterology, 2002,49 (48): 1579-1581.
66. Dohmoto M, Hunerbein M, Schlag PM. Palliatire endoscop ic therapy ofrectal carcinoma. Eur J Cancer, 1996, 32A: 25-29.
67. M cCaughan js Jr. Photodynamic gherapy, a review. Durgs Aging, 1999,15:49-68.
68. Gahlen J, Prosst RL, Stern J. Photodynamic therapy in the gastrointestinal tract Possibilities and limits. Chirurg, 2002, 73 (2): 122-131.
69. Schuh M, Nseyo UO, PotterWR, et al. Photodynamic therapy for palliation of locally recurrent breast carcinoma [ J ]. J Clin Oncol, 1987 (5): 1766—1770.
70. Bandieramonte G, Marchesini R, Melloni E, et al. Laser phototherapy following HpD administration in superficial neop lastic lesions [ J ]. Tumor, 1984, 70 (4) ,327—334.
71. Allison RR, Mang TS, Wilson BD. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies [ J ]. Semin CutanMed Surg , 1998, 17 (2) : 153-163.
72. Mang TS,Allison R, Hewson G, et al . A phase II/III clinical study of tin ethyl etiopurpurin (purlytin) - induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer [ J ]. Cancer J Sci Am , 1998, 4 (6): 378—384.
73. Cairnduff F, StringerMR, Hudson EJ, et al. Superficial photodynamic therapy with top ical 5 - aminolaevulinic acid for superficial p rimary and secondary skin cancer [ J ]. Br J Cancer, 1994, 69(3): 605-608.
74. Lapes M, Petera J, J irsa M. Photodynamic therapy of cutaneous metastases of breast cancer after local app lication of meso - tetra (para - sulphophenyl) - porphin ( TPPS4) [ J ]. J PhotochemPhotobiol, 1996, 36 (2): 205-207.
75. Bass P,Van Geel IP, Oppelaar H, et al. Enhancement of photodynamic therapy by Mitomycin C: a p reclinical and clinical study[ J ]. Br J Cancer, 1996, 73 (8) : 945～ 951.
76. Crescenzi E, Varriale L, IovinoM, et al. Photodynamic therapy with indocyanine green comp lements and enhances low - dose cisplatin cytotoxcity inMCF - 7 breast cancer cells [ J ]. Mol Cancer Ther, 2004, 3 (5): 537-544.
2.杨玲,李连弟,陈育德,等.中国肺癌死亡趋势分析及发病、死亡的估计与预测(J).中国肺癌杂志,2005,8(4):274.
3.许德余.肿瘤光动力疗法[M].北京:中国医药科技出版社,1996:88-95.
4.Evans AR,Limp-Foster M,Kelley MR.Going APE over ref-1.Mutat Res 2000;461:83-108
5.Shen JC,Loeb LA.Mutations in the alpha8 loop of human APE1 alter binding and cleavage of DNA containing an abasic site.J Biol Chem,2003,278(47):46994-47001.
6.Wong D,DeMott MS,Demple B.Modulation of the 3′→5′exonuclease activity of human apurinic endonuclease(Ape1) by its 5′-incised Abasic DNA product.J Biol Chem,2003,278(38):36242-36249.
7.Bennett RA,Wilson DM,Wong D,et al.Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway.Proc Natl Acad Sci USA,1997,94(14):7166-7169.
8.Marsin S,Vidal AE,Sossou M,et al.Role of XRCC1 in the coordination and stimulation of oxidative DNA damage repair initiated by the DNA glycosylase hOGG1.J Biol Chem,2003,278(45):44068-44074.
9.Tell G,Pines A,Paron I,et al.Redox effector factor-1 regulates the activity of thyroid transcription factor 1 by controlling the redox state of the N transcriptional activation domain.J Biol Chem,2002,277(17):14564-14574.
10.Borkhardt,A.Blocking oncogenes in malignant cells by RNA interference:new hope for a highly,specific cancer treatment.Cancer Cells,2002;2:167-168.
11.Volpers C,Kochanek S.Adenoviral vectors for gene transfer and therapy.J Gene Med,2004,Suppl 1:S164-71.
12.储大同.肺癌.北京:北京大学医学出版社.2007:7-14.
13.Angkeow P,Deshpande SS,Qi B et al.Redox factor-1:an extra-nuclear role in the regulation of endothelial oxidative stress and apoptosis.Cell Death Differ,2002,9(7):717-725
14.Hall JL,Wang X,Van Adamson et al.Overexpression of Ref-1 inhibits hypoxia and tumor necrosis factor-induced endothelial cell apoptosis through nuclear factor-kappab-independent and -dependent pathways.Circ Res,2001,88(12):1247-1253
15.Bennett RA,Wilson DM 3rd,Wong D,et al.Interaction of human apurinic endonuclease and DNA polymerase beta in the base excision repair pathway.Proc Natl Acad Sci USA,1997,94(14):7166-7169.
16.Fry WA,Phillips J,Menck H.Ten-year survey of lung cancer treatment and survival in hospitals in the United States:a national cancer data base report[J].Cancer,1999,86(9):1867-1876.
17.Friedberg EC.DNA damage and repair.Nature,2003,421(6921):436-440.
18.Ishikawa T,Samuel S.Zhang M.et al..DNA repair and cancer:Lessons from mutant mouse models.Cancer Sci 2004;95:112-117.
19.Bruner SD,Noman DP,Verdine CL et al.Structural basis for recognition and repair of the endogenous mutagen 8-oxogua in DNA.Nature,2000,403(6772):859
20.Wood RD,Mitchell M,Sgouros J et al.Human DNA repair genes.Science,2001,291(5507):1284
21.Evans AR,Limp-Foster M,Kelley MR.Going APE over ref-1.Mutat Res 2000;461:83-108
22.吕晓华,王瑞淑.Ref-1:一种调节细胞氧化还原状态的多功能蛋白质.国外医学分子生物学分册 2001;23(3):65-9
23.Puglisi F,Barbone F,Tell G et al.Prognostic role of Ape/Ref-1 subcellar expression in stage Ⅰ-Ⅲ breast carcinomas.Oncol Rep,2002,9(1):11-17
24.Moore DH,Michael H,Tritt R et al.Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers.Clin Cancer Res,2000,6(2):602-609
25.Kelley MR,Cheng L,Foster R et al.Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer.Clin Cancer Res,2001,7(4):824-830.
26.Kakolyris S,Kaklamanis L,Giatromanolaki A,et al.Expression and subcellular locaLization of human AP endonuclease 1(HAP1/Ref-1) protein:a basis for its role in human disease[J].Histopathology,1998,33(6):561-569.
27. TELL G, DAMANTE G,1 CALDWELL D, et al. The Intracellular Localization of APE1/Ref-1:More than a Passive Phenomenon? Antioxid. Redox Signal. 7, 2005(3,4):367 - 384.
28. Herring CJ, West CM, Wilks DP, et al. Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivityof cervical cancers. Br J Cancer. 1998, 78(9): 1128-1133
29. Puglisi F, Aprile G, Minisini AM, et al. Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas. Anticancer Res 2001;21(6A):4041-9.
30. Kakolyris S, Giatromanolaki A, KoukourakisM, et al. Nuclear location of human AP endonuclease 1 (HAP1/Ref-1) associates with prognosis in early Operable non-small cell lung cancer (NSCLC) [J]. J Pathol, 1999, 189(3): 351-357.
31．仲召阳,王东,李增鹏,等。骨肉瘤中APE1的表达及其与血管生成的关系[J]。 第三军医大学学报,2005,27(10)：1045-1048．
32. Killilea DW, Hester R, Balczon R, et al. Free radical production in hypoxic pulmonary artery smooth muscle cells. Am J Physiol Lung Cell Mol Physiol, 2000, 279(2): L408-412.
33. Grishko V, Solomon M, Breit JF, et al. Hypoxia promotes oxidative base modifications in the pulmonary artery endothelial cell VEGF gene. FASEB J, 2001, 15(7): 1267-1269.
34. Ziel KA, Campbell CC, Wilson GL, et al. Ref-1/Ape is critical for formation of the hypoxia-inducible transcriptional complex on the hypoxic response element of the rat pulmonary artery endothelial cell VEGF gene. FASEB J, 2004, 18(9): 986-998.
35. Hall JL ,Wang X, Van Adamson V, et al. Overexpression of Ref-1 inhibits Hypoxia and tumor necrosis factor-induced endothelial cell apoptosis Through nuclear factor-kappab-independent and-dependent pathways[J]. CircRes, 2001, 88(12): 1247-1253.
36. Thomas J. Dougherty, Charles J. Gomer, Barbara W. Henderson, et al. Photodynamic therapy. J Natl Cancer Inst 1998;90:889-905
37. Zhu TC, Hahn SM, Kapatkin AS, et al. In vivo optical properties of normal canine prostate at 732nm using motexafin lutetium-mediated photodynamic therapy[J]. Photochem Photobiol, 2000,77(1): 81-8.
38. Akita Y, Kozaki K, Nakagawa A, et al. Cyclooxygenase-2 is a possible target of treatment approach in conjunction with photodynamic therapy for various disorders in skin and oral cavity [J]. Br J Dermatol, 2004,151(2): 472-80.
39. Wang D, Luo M, Kelley MR. Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition. Mol Cancer Ther, 2004, 3(6): 679-686.
40. Fung H, Demple B. A vital role for Apel/Refl protein in repairing spontaneous DNA damage in human cells, Mol Cell, 2005, 17(3):463-470.
41. Raffoul JJ, Banerjee S , Gupta VS, et al. Down-regulation of Apurinic/Apyrimidinic Endonuclease 1/Redox Factor-1 Expression by Soy Isoflavones Enhances Prostate Cancer Radiotherapy In vitro and In vivo. [J]Cancer Res 2007;67(5):2141 - 9.
42. Nguyen T, Menocal EM, Harborth J, Fruehauf JH, et al. RNAi therapeutics: An update on delivery.. Curr Opin Mol Ther. 2008 10(2): 158-167.
43. Paddison PJ ,Caudy AA ,Hannon GJ . Stable suppression of gene expression by RNAi in mammalian cells (J) . Proc Natl Acad Sci USA ,2002 ,99 (3): 1443.
44. Brummelkamp TR ,Bernards R ,Agami RA. System for stable expression of short interfering RNAs in mammalian cells (J ) . Science ,2002 ,296 (5567) :550.
45. Paul CP , Good PD ,Winer I ,et al . Effective expression of small interfering RNA in human cells (J ) . Nature Biotechnology ,2002 ,20 (5):505.
46. Shuey D , McCallus DE , Giordano T. RNAi : gene silencing in the rapeutici intervention (J) . Drug Discov Day , 2002 , 7 ( 20): 1040.
47. Fan Z, Beresford PJ, Zhang D, et al. Cleaving the oxidative repair protein Apel enhances cell death mediated by granzyme A. Nat Immunol, 2003, 4(2): 145-153.
48. Renee Ho, Lyudmila I. Rachek, Yi Xu, et al. Yeast apurinic/apyrimidinic endonuclease Apnl protects mammalian neuronal cell line from oxidative stress. J. Neurochem. 2007, 7( 10): 1459-1471.
49. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res, 2006, 4(3): 218-227.
50. Weber W, Fussenegger M. Pharmacologic transgene control systems for gene therapy [J] . J Gene Med , 2006 , 8(5) :533-534.
51. Peng Z. Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum Gene Ther, 2005, 16(9): 1016-1027.
52. .Buchschacher GL . Introduction to retroviruses and retroviral vectors [J ] . Somat Cell Mol Genet, 2001 ,26(1): 1211.
53. J ames B , Wechuck , Ozuer A , et al . Effect of temperature ,medium composition , and cell passage on production of herpesbased viral vectors [J ] . Biotech and Bioengin,2002,79(1):112-119.
54. Mona ha n PE , Samulski RJ . Adeno-associated virus vectors for gene therapy:more pros than cons [J ] . Mol Med Today , 2000 ,6 (2) :433-440.
55. Roth JA , Cristiano RJ. Gene therapy for cancer: what have we done and where are we going [J] . J Natl Ca ncer Inst, 1997 , 89(1) :21-39.
56. Gomez-Navarro J , Curiel DT , Douglas JT. Gene therapy for cancer [J] . Eur J Cancer , 1999 , 35 (3) :867-885.
57. Hit t MM , Gauldie J . Gene vectors for cytokine expression in vivo [J ] . Cur r Pharm Des , 2000 , 6 (3) :613-632.
58. Mountain A. Gene therapy : the f irst decade [ J ] . Trends Biotechnol , 2000 , 18 (1):119-128.
59. George JA. Gene therapy progress and prospects: adenoviral vectors [J ] . Gene Ther, 2003, 10(6) :1135-1141.
60. Romano G , Michell P , Pacilio C , et al . Latest developments in gene transfer technology : achievements , perspectives , and controversies over therapeutic applications [ J ] . Stem Cells , 2000 ,18(1): 19-39.
61. .Nishikawa M , Huang L . Non viral vectors in the new millennium:delivery barriers in gene transfer [J ] . Hum Gene Ther, 2001 ,12(4):861-870.
62. Thomas A , Ratko T , Joseph P , et al . Clinical Gene Therapy for Nonmalignant Disease [J ] . The American J of Med , 2003 ,115 (3) :560-569.
63. Kminiski JM , Huber MR , Summers JB , et al . Design of anonviral vector for site-selective , efficient integration into the human genome [J ] . FASEB J , 2002 ,16 (10): 1242-1247.
64. Emery DW , Yannaki E , Tubb J , et al . A chromatin insulator protects retrovirus vectors from chromosomal position effects[J ] . Proc Natl Acad Sci USA , 2000 , 97 (10):9150-9155.
65. Wu N , Watkins SC , Schaffer PA , et al . Prolonged gene expression and cell survival after infection by a herpes simplex virus mutant defective in the immediate early genes encoding ICP4、 ICP27 and ICP22 [J ] . J Virol, 1996 , 70 (6) :6358-6369.
66. .Marconi P , Krisky D , Oligino T , et al . Replication-defective herpes simplex virus vectors for gene transfer in vivo [J] . ProcNatl Acad Sci USA , 1996 , 93:11319-11320.
67. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE , et al . Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
68. Duxbury MS,Matros E,Ito H,et al.Systemic siRNAmediatedgene silencing:a new approach to targetedtherapy of cancer[J].Ann Surg,2004,240(4):667.
69. .Reuven Agami. RNAi and related mechanisms and their potential use for therapy. Current Opinion in Chemical Biology, 2002, 6: 829-834.
70. .Harbort h J , Elbashir S M , Bechert K, et al . Identification of essential genes in cultured mallian cells using small interfering RNAs. J Cell Sci ,2001 , 114(24):4557-4565.
71. Gonzalez-Santos ,Juana M , Cao H , et al . A complementation method for functional analysis of mammalian genes. NucleicAcids Res ,2005 ,33 (10): 94.
72. .Brummelkamp TR, Bernards R, Agami R.A system for stable expression of short interfering RNAs in mammalian cells. Science, 2002, 296(5567): 550-553.
73. Ghosh SS, Gopinath P, Ramesh A. Adenoviral vectors: a promising tool for gene therapy. Appl Biochem Biotechnol, 2006, 133(1): 9-29.
74. Majhen D, Ambriovic-Ristov A. Adenoviral vectors-How to use them in cancer gene therapy? Virus Res, 2006,119(2): 121-133.
75. .Relph KL, Harrington KJ, Pandha H. Adenoviral strategies for the gene therapy of cancer. Semin Oncol, 2005, 32(6): 573-582.
76. Lee YJ, Imsumran A, Park MY, et al. Adenovirus expressing shRNA to IGF-1R enhances the chemosensitivity of lung cancer cell lines by blocking IGF-1 pathway. Lung Cancer, 2007, 55(3): 279-286.
77. Lin L, Chen L, Wang H, et al. Adenovirus-mediated transfer of siRNA against Runx2/Cbfa1 inhibits the formation of heterotopic ossification in animal model. Biochem Biophys Res Commun, 2006, 349(2): 564-572.
78. Koizumi N, Mizuguchi H, Hosono T, et al. Efficient gene transfer by fiber-mutant adenoviral vectors containing RGD peptide. Biochim Biophys Acta, 2001, 1568(1): 13-20.
79. Li Y, Pong RC, Bergelson JM, et al.. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. Cancer Res, 1999, 59(2): 325-330.
80. Miller CR , Buchsbaum DJ , Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res, 998, 58(24): 5738-5748.
81. Shayakhmetov DM, Papayannopoulou T, Stamatoyannopoulos G, et al. Efficient gene transfer into human CD34(+) cells by a retargeted adenovirus vector. J Virol, 2000, 74(6): 2567-2583.
82. Nilsson M , Ljungberg J , Richter J, et al. Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med, 2004, 6(6): 631-641.
83. Havenga MJ, Lemckert AA, Ophorst OJ, et al. Exploiting the natural diversity in adenovirus tropism for therapy and prevention of disease. J Virol, 2002, 76(9): 4612-4620.
84. McCaughan J S J r. Photodynamic therapy : a review. Drug Aging ,1999 ,15 (1) '. 49-68.
85．孟斌,温博贵,李冠武,等．肿瘤光动力疗法诱导细胞凋亡机制研究进展[J]．生理科学进展,2002,33(3)：269—272．
86. FingarVH, Kik PK, Haydon PS, et al. Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD)[ J ]. Br-J-Cancer, 1999, APR: 79 (11): 1702.
87. Agarwal ML , Clay ME , Harvey EJ , et al.Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res, 1991 , 51 ( 21 ) : 5993-5996.
88.Krammer B.Vascular effects of photodynamic therapy.Anticancer Res,2001,21(6B):4271-4277.
89.Gollnick SO,Vaughan L,Henderson BW.Generation of effective antitumor vaccines using photodynamic therapy.Cancer Res,2002,62(6):160421608.
90.Korbelik M,Sun J,Posakony JJ.Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors.Photochem Photobiol,2001,73(4):403-409.
91.Chiu SM,Oleinick NL.Dissociation of mitochondrial depolarization from cytochrome crelease during apoptosis induced by photodynamic therapy.Br J Cancer,2001,84(8):1099-1106.
92..Kim HR,Luo Y,Li G,et al.Enhanced apoptotic response to photodynamic therapy after bcl22 transfection.Cancer Res,1999,59(14):3429-3432.
93.赵玉沛,杨波,张太平,等.血卟啉衍生物光动力作用杀伤人胰腺癌细胞的实验研究[J].中华外科杂志,2000,38(3):204-207。
94.Olive PL.DNA damage and repair in individual cells:applications of the comet assay in radiobiology.Int J Radiat Biol,1999,75(4):395-405.
95.Wang HW,Putt ME,Emanuele M J,et al.Treatment-induced changes in tumor oxygenation predict photodynamic therapy outcome[J].Cancer Res,2004,64(20):7553-61.
96.Masumoto K,Yamada I,Tanaka H,et al.Tissue distribution of a new photosensitizer ATX-S 10Na(Ⅱ) and effect of a diode laser(670nm) in photodynamic therapy[J].Lasers Med Sci,2003,18(3):134-8.
97.Ahmad N,Mukhtar H.Mechanism of photodynamic therapy-induced cell death[J].Methods Enzymol,2000,319:342-58.
98.Dolmans DE,Fukumura D,Jain RK.Photodynamic therapy for cancer.Nat Rev Cancer 2003;3:380-7.
99.Brown SB,Brown EA,Walker I.Photodynamic Therapy(PDT) for Malignant and Pre-malignant Indications.Lancet Oncol.2004 Aug;5(8):497-508
100.Lai J,Tao Z,Xiao J,et al.Effect of photodynamic therapy(PDT) on the expression of proapoptotic protein Bak in nasopharyngealcarcinoma(NPC).Lasers Surg Med,2001,29(1):27-32.
101.Uehara M , Inokuchi T , Sano K, et al. Expression of vascular endothelial growth factor in mouse tumours subjected to photodynamic therapy. Eur J Cancer ,2001 ,37 (16) : 2111-2115.
102.Korbelik M , Sun J , Posakony JJ . Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem Photobiol ,2001 ,73 (4) : 403-409.
103.Orenstein A ,Kostenich G ,Roitman L ,et al. A comparative study of tissue distribution and photodynamic therapy selectivity of chlorine- e6 ,Photofrin II and ALA2induced protoporp hyrin Kinacolon carcinoma model (J ) .Br J Cancer ,1996 ,73 (8) :937.
104.Wyld L, Reed MW, Brown NJ. Differential cell death reponse to photodynamic therapy is dependent on dose and cell type[J]. Br J Cancer, 2001, 84(10): 1384-1386.
105.Xue L Y, He J , Oleinick NL. Rapid tyrosine phosphorylation of HS1 in the response of mouse lymphoma L5178Y2R cells to photodynamic treatment sensitized by the phthalocyanine Pc 4. Photochem Photobiol, 1997 , 66(1) :105-113.
106.Ruck A, Heckelsmiller K, Kaufmann R, et al. Light-induced apoptosis involves a defined sequence of cytoplasmic and nuclear calcium release in lPcS4-photosensitized rat bladder RR 1022 epithelial cells[J]. Photochem Photobiol, 2000, 72(2):210-216.
107.Silva JC, Lacava ZG, Kuckelhaus S, et al. Evaluation of the use of low level laser and photosensitizer drugs in healing[J]. Lasers Surg Med, 2004, 34(5):451-457.
108.Uzdensky A, Juzeniene A, Ma LW, et al. Photodynamic inhibition of enzymatic detachment of human cancer cells from a substratum. [J]. Biochim Biophys Acta 2004 Jan; 1670(1): 1-11.
109.Walker LJ, Craig RB, Harris AL, et al. A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res, 1994, 22(23):4884-4889.
110.Ono Y, Furuta T, Ohmoto T, et al. Stable expression in rat glioma cells of sense andantisense nucleic acids to a human multifunctional DNA repair enzyme APEX nuclease. Mutat Res, 1994, 315(1):55-63.
111.McNeill DR, Wilson DM 3rd. A dominant-negative form of the major human abasicendonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol Cancer Res, 2007, 5(1):61-70.
112..Yang ZZ,Chen XH,Wang D.Experimental study enhancing the chemosensitivity of multiple myeloma to melphalan by using a tissue-specific APE1-silencing RNA expression vector.Clin Lymphoma Myeloma.2007,7(4):296-304.
113.孙敬方.动物实验方法学[M].北京:人民卫生出版社,2001:391-396.
114.Rygaard J,Povlsen CO.Heterotransplantation of a human malignant tumor to 'nude'mice[J].Acta Path Microbiol Scand,1969;77:758-760.
115.田庆锷,李玛琳.人肿瘤细胞悬液裸鼠皮下接种及影响移植成功的因素[J].实验动物科学与管理,2004;21:47-48.
116.An Z,Wang X,Kubota T,et al.A clinical nude mouse metastatic model for highly malignant human pancreatic cancer[J].Anticancer Res,1996,16(2):627-631.
117.Shoji T,Konno H,Sakaguchi T,et al.Orthotopic implantation of a colon cancer xenograf t induces high expression of cyclooxygenase-2[J].Cancer Lett,2003,195(2):235-241
118.Tanaka E,Yamashita J,Hayashi N.A pulmonary metastatic model of human non-small cell lung carcinoma cells that produce a neut rophil elastase21ike molecule in severe combined immunodeficiency mice[J].Chest,2003,123(4):1248-1253.
119..王允,周清华,覃扬,等.外源性FHIT基因表达对肺腺癌细胞株A549恶性表型的逆转作用[J].中华医学遗传学杂志,2002,19(3):225-229.
120..Enebrecht BW,Menon C,Kachur AV,et al.Photofrin2mediated photodynamic therapy induces vascular occlusion and apoptosis in a humansarcoma xenograft model.Cancer Res,1999,59:4334-4342.
121.Fingar VH,Wieman TJ,Doak KW.Role of thromboxane andprostacyclin release on photodynamic therapy2induced tumor destruction.Cancer Res,1990,50:2599-2603.
122.Uehara M,Inokuchi T,Sano K,et al.Expression of vascular endothelial growth factor in mouse tumours subjected to photodynamic therapy.Eur J Cancer,2001,37(16)2111-2115.
123.Renno RZ,Delori FC,Holzer RA,et al.Photodynamic therapy using Lu-Tex inducesapoptosis in vitro,and its effect is potentiated by angiostatin in retinal capillary endothelial cells.Invest Ophthalmol Vis Sci,2000,41(12):3963-3971.
1.McCaughan J S J r.Photodynamic therapy:a review.Drug Aging,1999,15(1)49-68.
2.Lipson RL,Baldes EJ,Olaen AM.The useof derivative of hematoporphyrin in tumor detection.J Natl Cancer Inst,1961,26(1):1-8.
3.Hayata Y,Kato H,Konaka C,et al.Fiberoptic bronchoscopic laser photoradiation for tumor localization in lung cancer.Chest,1982,82(1):10-14.
4..Dolmans D,Fukumura D,Jain R.Photodynamic therapy for cancer[J].Nat Revancer,2003,3(5):380-387.
5.Bonnett R.Photosensitizers of porp hyrin and p ht halocyanine series for photodynamic t herapy[J].Chem Soc Rev,1995,24:19.
6.Kennedy J C.ALA2PDT An Overview[J].Photochemist ry and Photobiology.(Supply),1993,57:765.
7.Kawamoto C.Proceedings of the 1st International Conference on the Clinical Applications of Photosensitization for Diagnosis and Treatment[J].Tokyo,Japan,1986:130.
8.Scott LJ,Goa KL.Verteporfin.Drugs Aging,2000,16(2):139-146.
9..陈五高.激光治癌[M].武汉:华中师范大学出版社,1993:202.
10.Moghissi K,Dixon K.Is bronchoscopic photodynamic therapy a therapeutic option in lung cancer? Eur Respir J,2003,22(3):535-541.
11.凌一鸣.脉冲激光和连续激光作光动力学治疗作用机制差异的探讨.中国激光医学杂志,1994,3(3):178.
12.Patelli M,Lazzari Agli L,Poletti V,et al.Photodynamic laser therapy for the treatment of early2stage bronchogenic carcinoma.Monaldi Arch Chest Dis,1999,54(4):315-318.
13.Huang Z,Chen Q,Shakil A,et al.Hyperoxygenation enhances the tumor cell killing of photofrin-mediated photodynamic therapy.Photochem Photobiol.2003Nov;78(5):496-502.
14.Chen Q,Huang Z,Chen H,et al.Improvement of tumor response by manipulation of tumor oxygenation during photodynamic therapy. Photochem Photobiol. 2002 Aug;76(2):197-203
15.Matzi V, Maier A, Sankin O, et al., Photodynamic therapy enhanced by hyperbaric oxygenation in palliation of malignant pleural mesothelioma: clinical experience. Photodiag Photodyn Therapy 2004; 1:57-64
16. Huang Z, Chen Q, Chen H, ,et al., Effects of Pd-bacteriopheophorbide (TOOKAD)-Mediated Photodynamic Therapy on Canine Prostate Pretreated with Ionizing Radiation . Radiat Res. 2004 June; 161(6): 723-731.
17. Uzdensky A ,J uzeniene A ,Ma L ,et al. Photodynamic inhibition of enzymatic detachment of human cancer cells from a substratum[J] . Biochim Biophyscta ,2004 ,1670(1): 1-11.
18. Agarwal ML , Clay ME , Harvey EJ , et al.Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res , 1991 , 51 (21 ) : 5993-5996.
19. Lai J , Tao Z , Xiao J , et al. Effect of photodynamic therapy ( PDT) on the expression of proapoptotic protein Bak in nasopharyngeal carcinoma (NPC) . Lasers Surg Med ,2001 ,29(1) :27-32.
20. Chiu SM , Oleinick NL. Dissociation of mitochondrial depolarization from cytochrome crelease during apoptosis induced by photodynamic therapy. Br J Cancer , 2001 , 84 (8) : 1099-1106.
21. Almeida RD, Manadas BJ, Carvalho AP, et al. Intracellular signaling mechanisms in photodynamic therapy [ J ]. Biochim Biophys Acta, 2004, 1704:59-86
22. Piette J, Volanti C, Vantieghem A,et al. Cell death and growth arrest in response to photosensitizers[ J].Biochem Pharmacol,2003,66:1651-1659.
23. Whitacre CM,Satoh TH,Xue L,et al.Photodynamic therapy of human breast cancer xenografts lacking caspase3[J].Cancer Lett,2002,179:43-49.
24. He J,Agarwal ML,Larkin HE,et al.The induction of partial resistance . Photochem Photobiol, 1996,64:845-852.
25. Zhou ZH, Yang HG, Zhang ZY, et al.. Role of calcium in phototoxicity of 2-butylamino-2-demethoxy-hypocrellin A to human gastric cancer MGC-803. Biochim BiophysActa 2003; 1593: 191-200
26. DING X, XU Q, LIU F, et al. Hematoporphyrin monomethyl ether photodynamic damage on HeLa cells by means of reactive oxygen species production and cytosolic free calcium concentration elevation Cancer Letter, 2004,216(1):43-54
27. Du, H Y et al. Photoactivation of hypericin down-regulates glutathione S-transferase activity in nasopharyngeal cancer cells Cancer Lett, 2004,207:175-81
28. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what,where,why,and how[J].Photochem Photobiol Sci,2002, 1:1-21.
29. Henderson B , Fingar V. Oxygen limitation of direct tumor cell kill during photodynamic treatment of a murine tumor model [J] .Photochem Photobiol , 1989 , 49 ( 3 ): 299-304.
30. Kobayashi W,Liu Q ,Matsumiya T ,et al.Photodynamic therapy upregulates expression of Mac - 1 and generation of leukotriene B ( 4 ) by human polymorphonuclear leukocytes [ J ] . Oral Oncol, 2004 ,40 (5) .506-510.
31.Krammer B. Vascular effects of photodynamic therapy. Anticancer Res , 2001 , 21 (6B) :4271-4277.
32. Dolmans DE , Kadambi A , Hill J S , et al.Vascular accumulation of a novel photosensitizer , MV6401 , causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res, 2002 , 62 ( 7 ) :2151-2156.
33. Henderson BW, Sitnik2Busch TM , Vaug-han LA. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent .Photochem Photobiol ,1999 ,70 (1) : 64-71.
34. Uehara M , Inokuchi T , Sano K, et al. Expression of vascular endothelial growth factorin mouse tumours subjected to photodynamictherapy. Eur J Cancer ,2001 ,37 (16) : 2111-2115.
35. Renno RZ , Delori FC , Holzer RA , et al.Photodynamic therapy using Lu2Tex induces apoptosis in vitro , and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci ,2000 ,41 (12) : 3963-3971.
36. Ichikawa K, Takeuchi Y, Yonezawa S , et al. Antiangiogenic photodynamic therapy( PDT ) using Visudyne causes effective suppression of tumor growth [ J ] . Cancer Lett ,2004 ,205 (1):39-48
37. Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamictherapy. Cancer Res 1996;56:5647-52.
38. Cecic I, Korbelik M, et al. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumours. Cancer Lett 2002; 183: 43-51.
39. Gollnick SO , Vaughan L , Henderson BW.Generation of effective antitumor vaccines using photodynamic therapy. Cancer Res : 2002 ,62 (6) : 1604-1608.
40. Gollnick SO, Owczarczak B, Maier P. Preclinical Reports Photodynamic therapy and anti-tumor immunity [ J ] . Lasers in Surgery and Medicine,2006, 38( 5): 509 - 515
41. Korbelik M , Sun J , Posakony JJ . Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem Photobiol ,2001 ,73 (4) : 403-409.
42. Dougherty TJ , Gomer CJ , Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst, 1998 ,90(12) : 889-905.
43. Dougherty TJ . An update on p hotodynamic t herapy applications (J) J Clin Laser Med Sury,2002,20(1):3.
44. Edell ES , Cortese DA. Photodynamic therapy in the management of early superficial squamous cell carcinoma as an alternative to surgical resection. Chest , 1992 , 102 (5) : 1319-1322.
45. Furuse K, Fukuoka M , Kato H , et al. A prospective phase II study on photodynamic therapy with photofrin II for centrally located early2stage lung cancer. The Japan LungCancer Photodynamic Therapy Study Group.J Clin Oncol ,1993 ,11 (10) : 1852-1857.
46. Kato H. Photodynamic therapy for lung cancer-a review of 19 years' experience. J Photochem Photobiol B ,1998 ,42 (2) : 96-99.
47. Dougherty TJ , Gomer CJ , Henderson BW, et al. Photodynamic therapy. J Natl Cancer Inst, 1998 ,90(12) :889-905.
48.Moghissi K,Dixon K,Hudson E,et al.Endoscopic laser therapy in malignant tracheobronchial obstruction using sequential Nd-YAG laser and photodynamic therapy.Thorax,1997,52(3):281-283.
49.Moghissi K,Dixon K,Stringer M,et al.The place of bronchoscopic photodynamic therapy in advanced unresectable lung cancer:experience of 100 cases.Eur J Cardiothorac Surg,1999,15(1):126.
50.Overholt BE Panjehpour M,Haydek JM.Photodynamic therapy for Barrett's esophagus:follow-up in 100 patients.Gastrointest Endosc,1999,49:123-226
51.Savarf JF,Grosjean P,Monnier P,et al.Photodynamic therapy of early squamous cell carcinomas of the esophagus:a review of 31 cases.Endoscopy,1998,30(3):258-263
52.张南征,朱云,潘武等.光动力疗法治疗食管贲门癌110例分析.徐州医学院学报,2001,21(4):291-294.
53.林文杰,陈俊辉,王少彬等.Photofrin光动力治疗食管癌近期疗效观察.医药产业资讯,2005,2(11):15-17
54.沙卫红,李瑜元,聂玉强等.光动力疗法与支架防止术治疗进展期食管癌比较.中华消化内镜杂志,2006,23(1):27
55.Ana P.Castano,PawelMrozMichael R.Hamblin,Photodynamic therapy and anti-tumour immunity.Nature Rev,2006,7(6):535
56.Sun,S.C.&Xiao,G.Deregulation of NF-κB and its up stream kinases in cancer.CancerMetastasis Rev,2003,22:405
57.Korbelik,M.& Sun,J.Cancer treatment by photodynamic therapy combined with adop tive immunotherapy using genetically altered natural killer cell line.Int.J.Cancer 2001,93-96.
58.Holyoke ED.New surgical approaches to pancreatic cancer.Cancer,1981,47(6):1719-1723.
59.Bown SG,Rogowska AZ,Whitelaw DE,et al.Photodynamic therapy for cancer of the pancreas.Gut,2002,50(4):549-557.
60.Laftavi MR,Lens P,Margonari J,et al.Photodynamic therapy can selectively eradicate pancreas exocrine secretion.Transplant Proc,1998,30(2):596-598.
61.Rahbar M,Lenz P,Margonari J,et al.Destruction of rat exocrine pancreatic tissue by photodynamic therapy. Transplant Proc , 1997 ,29 (7): 2904-22907.
62. Nakamura H, yanai H, Nishikawa J, et al. Experience with photodynamic therapy (endoscop ic laser therapy) for the treatment of early gastric cancer. Hepatogastroenterology, 2001, 48: 1599-1603.
63. Haramura T, Fukui H, Ishii Y, et al. Shape memory alloy loop snare for endoscop ic photodynamic therapy of early gastric cancer. Endoscopy, 2000, 32 (8): 69.
64. Yanai H, Kuroiwa Y, Shimizu N, et al. The pilot experience of immunotherapycombined photodynamic therapy for advanced gastric cancer in elderly patients. Int J Gastrointest Cancer, 2002, 32 (223): 139-142.
65. Karanow SI. Long term results after photodynamic therapy (PDT) of T1N0M0 gastrointestinal ( GI) tumors. Hepatogastroenterology, 2002,49 (48): 1579-1581.
66. Dohmoto M, Hunerbein M, Schlag PM. Palliatire endoscop ic therapy ofrectal carcinoma. Eur J Cancer, 1996, 32A: 25-29.
67. M cCaughan js Jr. Photodynamic gherapy, a review. Durgs Aging, 1999,15:49-68.
68. Gahlen J, Prosst RL, Stern J. Photodynamic therapy in the gastrointestinal tract Possibilities and limits. Chirurg, 2002, 73 (2): 122-131.
69. Schuh M, Nseyo UO, PotterWR, et al. Photodynamic therapy for palliation of locally recurrent breast carcinoma [ J ]. J Clin Oncol, 1987 (5): 1766—1770.
70. Bandieramonte G, Marchesini R, Melloni E, et al. Laser phototherapy following HpD administration in superficial neop lastic lesions [ J ]. Tumor, 1984, 70 (4) ,327—334.
71. Allison RR, Mang TS, Wilson BD. Photodynamic therapy for the treatment of nonmelanomatous cutaneous malignancies [ J ]. Semin CutanMed Surg , 1998, 17 (2) : 153-163.
72. Mang TS,Allison R, Hewson G, et al . A phase II/III clinical study of tin ethyl etiopurpurin (purlytin) - induced photodynamic therapy for the treatment of recurrent cutaneous metastatic breast cancer [ J ]. Cancer J Sci Am , 1998, 4 (6): 378—384.
73. Cairnduff F, StringerMR, Hudson EJ, et al. Superficial photodynamic therapy with top ical 5 - aminolaevulinic acid for superficial p rimary and secondary skin cancer [ J ]. Br J Cancer, 1994, 69(3): 605-608.
74. Lapes M, Petera J, J irsa M. Photodynamic therapy of cutaneous metastases of breast cancer after local app lication of meso - tetra (para - sulphophenyl) - porphin ( TPPS4) [ J ]. J PhotochemPhotobiol, 1996, 36 (2): 205-207.
75. Bass P,Van Geel IP, Oppelaar H, et al. Enhancement of photodynamic therapy by Mitomycin C: a p reclinical and clinical study[ J ]. Br J Cancer, 1996, 73 (8) : 945～ 951.
76. Crescenzi E, Varriale L, IovinoM, et al. Photodynamic therapy with indocyanine green comp lements and enhances low - dose cisplatin cytotoxcity inMCF - 7 breast cancer cells [ J ]. Mol Cancer Ther, 2004, 3 (5): 537-544.